OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2024-12-31-accounts

Charity registration number 1188298 (England and Wales)

Company registration number 11785842

SUCCESS LIFE AFTER CURE LIMITED

ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

SUCCESS LIFE AFTER CURE LIMITED

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees Philip Austin
Jane Hobson
Hugh Stewart
Jennifer Limond
Marco Previero
Dr Helen Spoudeas
Dr Jane Williams
Richard Crowther (Retired by rotation,
9thFebruary 2024)
Charity number (England and Wales) 1188298
Company number 11785842
Registered office 280 Bishopsgate
London
EC2M 4RB
Independent examiner Tom Wilcox
Counterculture Partnership LLP
Bank Chambers
Main Street
Hawes
North Yorkshire
DL8 3QL

SUCCESS LIFE AFTER CURE LIMITED

CONTENTS

Page
Chair's Report 1 - 3
Trustees' report 4 - 16
Independent examiner's report 18
Statement of financial activities 19
Balance sheet 20
Notes to the financial statements 21 - 29

SUCCESS LIFE AFTER CURE LIMITED

CHAIR'S REPORT

FOR THE YEAR ENDED 31 DECEMBER 2024

FOUNDER / CEO's REPORT

The Directors have pleasure in presenting their report and the financial statements for the charitable company for the year ended 31 December 2024. The Directors have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) (effective 1 January 2019).

Cure Alone Is Not Enough

At SUCCESS, we remain steadfast in our belief that curing childhood brain tumours, without also curing the underlying brain injury, is not enough. Survival must come with a future - one that restores health, cognitive potential, independence, and partnership and employment opportunities; the key ingredients to a quality life and one worth living. With 80% of children now looking forward to a near normal life-span, and the rest still subjected to intense experimental therapies, we can no longer ignore their moral right to comprehensive complex needs assessments and neurorehabilitation as part and parcel of their cancer treatment; from the very beginning and throughout the life span.

We now have evidence from the North Thames Cancer Network that less than 50% of patients and their neurooncology professionals recognise a child's need for neurorehabilitation or specific educational support and only 6% received streamlined neurorehabilitation post-operatively. We know it is especially important to keep up with complex needs assessments throughout the four key maturational stages of the growing body and brain, [infancy, childhood, adolescence and young adulthood], and to provide tailored neurorehabilitation, alongside timely growth and other hormone replacement, whilst it has the greatest impact - before maturation is complete at 25 years of age. These services are not comprehensively provided in the cancer / late effects pathway and young adult survivors tell us they struggle to access co-ordinated holistic recovery care lifelong. We estimate 40,000 all-age survivors now exist across the UK, accruing by 1,000 every year, and need our advocacy and support.

Cure alone is not enough when:

Delivering on Our Vision

While advances in cancer research have improved survival, the cost of treatment to a developing child is often overlooked. SUCCESS remains committed to ensuring that every child's recovery is as complete as their cure, from diagnosis onwards.

To achieve this, we continue to push for a SUCCESS National Recovery Pathway, integrated within the NHS. This parallel system would provide tumour-specific rehabilitation from diagnosis through to adulthood, ensuring survivors thrive - not just survive. SUCCESS also recognises and champions a bespoke pathway for the few {<30 p.a.] very rare tumours of the vital deep midbrain [in the hypothalamus and pituitary] . Such endocrine tumours of the primitive master gland controlling life itself, though often low grade, are particularly problematic to children's development and sensitive to surgery; they require dedicated and experienced pituitary teams [often operating through the nose] for the best chance of a 'harmless' first time cure. This year SUCCESS stepped up its Parliamentary campaign to NHS England for equitable, bespoke pituitary care for those under 16 years, to be concentrated to a few national centres, as already exist for adults.

SUCCESS LIFE AFTER CURE LIMITED

CHAIR'S REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

Our vision and objectives

Streamlining existing NHS services to achieve cost-efficient, evidence-based reform requires navigating speciality and geographical complexity, engaging diverse professionals and commissioners beyond oncology, and making the most of limited resources. SUCCESS is committed to transforming healthcare delivery to improve secondary health outcomes by integrating brain injury evaluation and recovery from the start of the brain tumour journey.

To help us we are proud to have engaged a number of high profile NHS Clinicians and Parliamentarians to our Clinical and Parliamentary Advisory Groups. Key amongst them have been Professors David Walker and Darren Hargrave, together with Lord Sandhurst and Sir Bruce Keogh, alongside our patron Dominic Grieve KC. It is their wise counsel, actions and advocacy on our behalf at our conferences, in Parliament and from the House of Lords, that have gained us credence and an audience at NHSE in 2025.

This is an ambitious vision, and we have limited funds. In order to progress our agenda, we continue to breakdown our projects and initiatives across three key objectives which underpin our long term strategy - the next 5 years are pivotal as we set out our key goals across three strategic pillars:

1. Amplifying the Survivor Voice - Educational Networking & Research Participation

Over the next five years, SUCCESS aims to establish itself as the beacon gold standard in survivor-led advocacy, family education and empowerment, peer support, professional learning in survivorship and health evaluation research engagement. We will expand our biannual conferences, now attracting 100 -150 to close to 200 attendees in both London and at a northern regional centre, to include a CPD-accredited educational component for selffunded professionals a prize for the best research presentation, and a post-conference on-line highlights publication and virtual meeting. A pre-conference satellite meeting of a new national 'SUCCESSCONNECT' advocate group made up of parents / survivors, therapists, nurses and allied community professionals will also be established to promote and endorse the parallel nature of recovery and the recovery pathway.

These events will focus on health-related quality of life (HR-QoL) outcomes for brain tumour survivors, with travel grants and research awards to promote high-quality health evaluation studies. Additionally, SUCCESS will enhance its early role in Patient and Public Involvement (PPI) by actively trying to shape HR-QoL research in academic centres, neuro-oncology clinics, and as partners with major funding bodies like NIHR and brain tumour charities. Through our own BraveHearts Magazine publication, website blogs, and collaborative studies, we will amplify survivor perspectives and drive meaningful research impact in this neglected area.

2. Alleviating Suffering & Isolation - BraveHearts Programme

Building strong peer support networks amongst survivors, siblings and families, but also amongst professionals trying to support survivors beyond the cure itself, remains central to SUCCESS's vision. We will expand our BraveHearts Programme, the voice of SUCCESS, ensuring survivors and families have access to peer-to-peer support groups, interactive webinars, WhatsApp communities, and in-person events across the UK. A Survivor Manual, written by our 'BraveHearts', and further family publications will provide essential guidance, while dedicated summer camps for 15-25-year-olds will promote wellbeing, friendships, independence and vocational support, including the birth of a SUCCESS 'Etsy' shop to showcase their talents. Recognizing the critical gap in mental health services, we will develop an advisory service for education advice, psychology and neuropsychiatry, alongside a professional helpline. Additionally, we will strengthen survivor and parent councils, with lead trustees from each represented on the board, always ensuring dialogue between our beneficiaries and diverse medical experts on hand to provide advice, and fostering a supportive, informed community.

SUCCESS LIFE AFTER CURE LIMITED

CHAIR'S REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

3. Accelerating & Advocating NHS Service Reform - SUCCESS Recovery Pathway

SUCCESS is committed to transforming survivorship care by driving policy change and service innovation within the NHS. We will innovate with our Digital Therapy Programme with ReAbility UK, provide evidence of need by building on our North Thames Gap Analysis Study and continue to build a head of steam with our lobbying efforts towards endorsing and implementing the SUCCESS Recovery Pathway, integrating parallel complex needs neurorehabilitation and neuroendocrine [pituitary] services into survivorship care. Key milestones include securing commissioned implementation of our world-first national guidelines for centralized paediatric pituitary tumour services, commissioning targeted grant-funded studies into education, career opportunities, neurorehabilitation, and mental health outcomes, and achieving formal service specifications for brain tumour survivorship care. Over the next five years, the Digital Therapy programme will aim to evaluate goal-based and wellbeing outcomes in 300 children under 19 years, the first community programme of its kind to this cohort, providing a baseline report on this new technology against which to benchmark future development and delivery of such innovative platforms to make rehabilitation accessible throughout the life span and hence improve survivorship outcomes. Additionally, we will seek to establish the SUCCESS Keyworker Advocate role, to lead the SUCESSCONNECT national 'think tank' group with dedicated funding for an inaugural coordinator/trainer and the first cohort of trained advocates, positioning SUCCESS as a leader in survivorship advocacy and professional collaboration .

Thank you

We've made incredible strides this year, yet there is still much to be done ahead - 2024 has built on the success of 2023 and sharpened our focus on turning our vision into reality.

Despite doubling our conference and support offering in the last two years to include a northern cohort and some 1000 beneficiaries, within the same income generation of some £100,000 over the last 5 years, this has been achieved with much voluntary support and expertise from supporters and trustees for which I am exceptionally grateful. Our funds remain limited and there is now an urgency to regroup to generate the income needed to deliver and expand across the UK, the projects we have developed and begun. We are restructuring the board and the executive to prioritise fund raising against the urgency to progress across all fronts - doubling our beneficiary base, enhancing diagnostic complex needs assessments, establishing specialised paediatric pituitary tumour services, improving access to all forms of rehabilitative support, and creating a mandated, fully integrated and commissioned recovery pathway from the moment of diagnosis. After years of being overlooked, it is clear that through SUCCESS, this cause has not only found its voice but is finally being heard. Help us in achieving our vision for enabling a brighter, better future for every childhood brain tumour survivor.

I am so grateful to all our many parent, lay and professional volunteers, our donors, big and small, our board of trustees and patron, and to all the different medical professionals and Parliamentarians, who have contributed the much needed encouragement and valued support, formal and informal advice over the last year. We acknowledge and thank you all.

And last but never least, as always, I extend a heartfelt debt of thanks to our amazing BraveHearts, the cohort of courageous survivors and their families from whom we learn so much every day, whose voices we are proud to represent and for whom we exist to inspire others.

Dr Helen Spoudeas

Chairman

Date: 4 April 2025

SUCCESS LIFE AFTER CURE LIMITED

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)

FOR THE YEAR ENDED 31 DECEMBER 2024

The trustees present their annual report and financial statements for the year ended 31 December 2024.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charity's governing document, the Companies Act 2006, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)".

Objectives and activities

Objectives and aims

Success Charity - Life After Cure exists to enable brighter futures for childhood brain tumour survivors.

To promote and protect the physical and mental health, and relieve the needs of childhood brain tumour survivors ("survivors") treated in the United Kingdom by providing equipment, facilities and services not normally provided by the statutory authorities and in particular:

The Charity aims to achieve these objectives through a number of activities associated with its three driving ambitions of:

  1. Amplifying the voice of survivors and their families

  2. Alleviating social isolation for survivors and their families

  3. Accelerating rehabilitative services

The Trustees have considered the Charity Commission's guidance on public benefit, including the guidance "public benefit: running a charity (PB2)" and are satisfied that the aims of the Charity are carried out wholly in pursuit of its charitable aims for the public benefit.

SUCCESS LIFE AFTER CURE LIMITED

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Activities

Achievement and performance

Significant activities

Assessing Access to, and Knowledge of, Rehabilitation

North Thames Cancer Network Gap Analysis Study

SUCCESS has worked extensively to assess rehabilitation needs in 2024. Between October 2023 and August 2024, we commissioned a 9-month gap-analysis study with Great Ormond Street Hospital (GOSH) to capture in two timeperiods, the knowledge of, availability for, and quality of neurorehabilitative care evaluated against specified best practice NICE guidance since 2005, in a cross-sectional sample population of suvivors, parents and clinicians circumscribed to the North Thames Cancer Region.

This record review and questionnaire study showed significant lack of awareness amongst oncology professionals and families in how to refer or access educational and rehabilitative services in some 50%, with little difference between time cohorts, and only 6% receiving streamlined services in line with an acquired brain injury. This study's launch, with generous funding from The Gerald and Gail Ronson Family Foundation, was announced at our March 2024 London conference, initial findings being presented at our October Manchester Roadshow, with more detailed analysis, publication and dissemination to be pursued in 2025.

The Big Survivorship Survey

In Spring 2024 we also launched a national on-line survey through our website, with a BBC local radio-campaign to connect with all survivors of a brain tumour diagnosed before their 25th birthday, and ask them to provide their experiences on aftercure rehabilitation / recovery care in order to inform our NHS England campaign. This is an ongoing survey and to date of 50 responses, only 2 were aware that NICE had recommended rehabilitation to children with brain tumours back in 2005 .

Annual conference programmes - London & Manchester

Our Annual London Spring conference during brain tumour awareness month in March remains our flagship national event. We were thrilled to welcome 140 delegates to 1 Wimpole St, the home of The Royal Society of Medicine on March 2nd 2024, as well as Derek Thomas MP, chair of the All Party Parliamentary Group [APPG] on Brain Tumours, to take part in the final panel debate with Lord Sandhurst chaired by our patron Dominic Grieve KC. Our goal was to SHINE-Share, Innovate, Network, and Empower-and achieve 'Success-ful Destinations' across to advance Brighter Futures for Childhood Brain Tumour Survivors. For the first time, we also offered CPD training to new hospital and community professionals supporting recovery beyond cure. SUCCESS will continue to invest in its conference programme and plans are already underway to deliver on our 8th Annual Conference on 15th March 2025.

At the same time we launched our 2nd regional roadshow in Manchester on 19th October 2024, greeting some 70 delegates new to SUCCESS and bringing together 5 northern paediatric neuroncology centres, their professionals and their families [Manchester, Leeds, Liverpool, Nottingham, Sheffield], for the first time. We were delighted to have Professor Simon Kenney, NHSE s national clinical director for children, as our key guest speaker and to create new professional and patient connections suppoprtive of our work. We also engaged with the national group of paediatric neuro-oncology nurses at their annual meeting at the Christie hospital and introduced the idea of creating the SUCCESSCONNECT advocate group we are developing in 2025. We have scheduled our 3rd northern roadshow for 11th October 2025

Lobbying NHS England

This programme is critical to our desire to expand engagement across major paediatric neuro-oncology centres and engage decision-makers in NHSE and government to define a cost-efficient, safe and effective, integrated rehabilitation pathway, setting measurable goals for national implementation. To this end, we have had initial positive response from both NHS England and the Department of Health indicating their willingness to work with us to assess key gaps in service for this vulnerable population. This is indicative of the increasingly successful way in which we are lobbying for change through Parliament and NHSE with vital leadership from Lord Sandhurst and the support of our patron.

SUCCESS LIFE AFTER CURE LIMITED

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Building a sense of community

The cornerstone of our existence is building our community of survivors, their parents and families across the UK. We strive to support some 1000 current beneficiaries at face to face events such as our conferences, summer picnic and FUN-draising events and our much loved Christmas Carol Concert. We are expanding our Peer mentoring programmes to include parents and siblings whilst bringing training in-house, and enlarging our mediated online offering of weekly friendship and monthly themed Q/A groups, parent and survivor whatsapp support groups, an international health unlocked forum and increasing presence on social media, as well as our survivors' quarterly Braveheart magazine. We are also building a network of professionals and professional advisors making up our clinical advisory group, refreshing our website to make it user- and disabled- friendly, and with dedicated survivor and professional information sections. Our website is currently the main way in which our income is received.

More effective fundraising

This year, our second year in community fundraising, we doubled our community goals and achieved £28,000 and £33,000 with our Summer of FUN-draising and the Carol Concert respectively, whilst at the same time generating positive goodwill amongst our supporters, our beneficiaries and our major donor and corporate base. We also benefitted from £15,000 restricted grants (this is included in deferred income) from the William Rudd Trust to encourage beneficiary attendance at our conferences and £25,000 from a major donor to launch the Digital Therapy programme opening in 2025 after a 4-year delay to raise funds and insurance costs.

Achievements against objectives

Reducing Social Isolation for Survivors and their Families.

SUCCESS continues to develop peer networks that recognize cultural and social differences, helping survivors build relationships, improve mental health, and enhance education and employment outcomes.

Conference Programme

Annual London Conference

The 2024 SUCCESS Annual Conference, held at 1 Wimpole Street, London, on March 2nd, focused on "Successful Destinations" and brought together 140 participants at the Royal Society of Medicine. The event remains a powerful platform for survivors, families, professionals, and policymakers from which to raise awareness, foster positive interdisciplinary relationships, bridge gaps in care and forge change. The conference empowers survivors and professionals in both oncology and non-oncology disciplines, through sharing experiences and knowledge, highlighting service gaps, and advocating for a National SUCCESS Recovery Pathway determined by tumour location. Survivor- and professionally-led workshops, expert debate panels with patient representation, and expert networking sessions continue to provide invaluable support and education to families whilst also bringing together a diverse group of professionals striving to support many, as yet. under-recognised secondary health care needs.

We were delighted to welcome old and new faces from London and the South East, survivors from as young as 8 years and their families but also professionals including Mr Simon Cudlip, pituitary surgeon and Prof Marta Korbonits, pituitary tumour specialist, who explained the importance of new world-first guidelines for children and ensuring specialist care to outcomes. We are grateful to Drs Hoong We Gan, Manuela Cerbone, Charlotte Malcolm, Mr Kristian Aquilina, Profs Naomi Dale and Darren Hargrave, for their insight and understanding of how deep midbrain injury to the vital primitive hypothalamus affects all aspects of physiological and emotional well being and how effects might be minimised if rehabilitated in the right way. We also had a parallel symposium on specialist health and education services ably chaired by our new trustee Dr Jane Williams, a neurorehabilitation specialist, with her collleagues Drs Bishoti and Denise Crozier and a neuropsychiatrist Dr Ashley Liew, and a workshop led by the young people themselves with employment lawyers, educationalists and occupational therapist on overcoming barriers to education and employment. These conferences are unique in the way they bring together patients and diverse professionals, but also for having the attendance and support of eloquent Parliamentarians who are prepared to debate and help us shape our parliamentary and NHSE lobby towards implementation of both our new pituitary tumour management guidance and the tumour-site-specific parallel SUCCESS recovery pathway (Lord Sandhurst our lead, Derek Thomas MP and chair of the brain tumour APPG ), and Dominic Grieve KC, our supportive and thoughtful patron.

SUCCESS LIFE AFTER CURE LIMITED

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Our post-conference survey confirmed that over 90% of participants valued the conference as worthwhile and felt it addressed key objectives, namely: providing clarity on the importance of a parallel recovery pathway; improving understanding of the Charity's mission and aims; feeling more inclined to support us and to support survivors.

What participants liked most about the conference was gaining a better understanding of key challenges and finding support for them (54%) and feeling inspired and more hopeful about the future (31%). Overwhelmingly 85% of participants agreed the charity should continue to advocate for a parallel recovery pathway, from diagnosis and alongside oncology treatment.

Autumn Roadshow

Success Charity's 2nd Autumn Roadshow took place in Manchester on Saturday 19th October 2024, an ongoing educational initiative reaching all UK paediatric neuroncology centres was supported by satellite events on the 18th of October 2024. The primary goal of this event in line with the grant objectives, was to introduce SUCCESS to northern audience; educate, support and connect survivors of childhood brain tumours and their families with diverse oncology and rehabilitation healthcare professionals; raise awareness of gaps in neurological and endocrine recovery; highlight areas of good practice and connect with NHSE commissioners.

SUCCESS campaigns to raise awareness of the individual brain injury underlying each brain tumour, and the need for a parallel recovery pathway alongside cure, to improve long term health outcomes for the 80% that now survive and live long lives across the UK. This conference brought together a patient and professional audience from 5 northern paediatric neuro-oncology hospitals for the first time. In total 72 people attended this Roadshow, the majority of whom were beneficiaries of, and professionals linked to, the Charity.

Key activities included:

After the event, 89% of those surveyed told us they felt equally "inspired" and that "cure alone was not enough", whilst all felt a recovery pathway was indeed needed over and above what the NHS currently offered. Only 10% felt they had been supported through their recovery journey.

SUCCESS LIFE AFTER CURE LIMITED

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Voices of SUCCESS- The BraveHeart Programme

SUCCESS continues to amplify survivor stories and experiences through various initiatives:

Being a Catalyst for Innovation and Rehabilitative Services for Survivors

SUCCESS aims to facilitate and develop better access to, and increasing investment in, holistic (neuroendocrine) rehabilitation and health research interventions targeted at improving existing services, identifying new ones and facilitating better community health and educational access. This year, it has progressed this area through two major projects.

Survivorship Services Gap-Analysis Study in partnership with GOSH

SUCCESS commissioned a study evaluating access to rehabilitation services for childhood brain tumour survivors at the North Thames Paediatric Cancer Network (ODN), developed with Professor Darren Hargrave and therapists at GOSH with restricted funds from The Ronson Foundation and a smaller grant from our founder. A SUCCESSGOSH working group formed in 2022 led to the idea of the SUCCESS Recovery Pathway. The study, defined in July 2023 with Professor Hargrave and Dr Michalski, GOSH professionals and SUCCESS Trustees began in October 2023 with a part-time, neurophysiotherapist project lead.

The project aimed to survey recovery services against NICE recommendation standards (2005) and conduct a retrospective service review at 1-2 and 5-6 years post-diagnosis. Led by a Specialist Physiotherapist in Paediatric Neuro-Oncology at GOSH, Daniel Bell, it ran from November 2023 to August 2024, with main preliminary findings presented to trustees in September and in Manchester at the Autumn 2024 roadshow.

Amongst several interesting conclusions, the results of this retrospective gap-analysis reported that less than half (49) of 100 survivors surveyed, had received any rehabilitative or educational support and just 6% had received planned integrated support, even in the most recent cohort. None were aware of any educational tools to support cognitive weaknesses whilst under 50% knew how to access educational health care plan funding, and this figure was similar amongst oncology professionals.

With SUCCESS professionals and beneficiaries involved in designing the gap-analysis study and questionnaires, these findings support the proposed SUCCESS Survivorship Standards (SSS) for potential national endorsement in Phase 2, to be defined in 2025 and beyond, including our support of a collaborative PPI in the context of the Brain Tumour Charity and NIHR Quality of Life research. In this context we have also provided £5,505 to fund the PPI element of an NIHR grant awarded to Dr Charlotte Malcolm at GOSH to develop educational tools for strengthening cognitive weaknesses which SUCCESS will have access to once developed.

SUCCESS LIFE AFTER CURE LIMITED

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Digital Therapy Bursary Programme with our Partner ReAbility UK

SUCCESS has partnered with ReAbility Online UK to introduce a cutting-edge, games-based neurotherapy platform for children with brain tumours. Developed at the Gertner Institute, Israel, and widely used in Austria, this platform is unavailable in the UK, making SUCCESS the gateway for national implementation and evaluation.

Following a successful pilot study in 2020, presented at the British Paediatric Neurology Association, SUCCESS committed to fundraising, patient recruitment, and long-term programme evaluation. However, COVID insurance and funding challenges in 2021 delayed progress. In 2023, the project was revived, with a restructured protocol and renewed partnership, aiming to evaluate benefits in a total of 300 patients - recruited in tranches of 12-15 per quarter and treated over a 12 week period - according to adherence. Trustees Drs Jenny Limond and Helen Spoudeas and Jane Hobson have led clinical and legal protocol preparation and contractual agreements, and secured restricted funds to start the 12-week therapy programme for the first 25 patients. This has occurred alongside newly secured project management to finalise contractual terms to ensure the interests of beneficiaries and the Charity are prioritised, which has taken longer than anticipated. The launch was postponed with an anticipated date of 1.3.25 for training of UK therapists and patient recruitment, and a study start date of 1.6.25 . Continued efforts to prioritise fundraising to ensure the programme's success for the first 12 months and beyond this phase into 2nd and 3rd years .

Amplify the Voice of Survivors and their Families

SUCCESS strives to amplify the voices of survivors and families, addressing unmet needs, especially in hard-toreach and disadvantaged groups. SUCCESS believes that lobbying is vital to amplify the voices of survivors, ensuring their needs are heard at the highest levels. Without advocacy, critical gaps in rehabilitation, education, and healthcare remain overlooked. By engaging policymakers, SUCCESS aims to drive systemic change in the long term in order to secure equitable services for all, funding, and recognition for brain tumour survivors and their lifelong recovery needs.

The Charity's lobbying and advocacy efforts focus on key areas.

Lobbying Committee

Led by Lord Guy Sandhurst and Dr Helen Spoudeas since 2022, with input from SUCCESS parents, Lords Stewart Wood and Sharpe, and our Patron Dominic Grieve KC, this group advocates for national representation of the unmet recovery needs of survivors at parliamentary and NHSE levels. Over the last 12 months, our desire to expand engagement across major centres and decision-makers in NHSE and government to define a cost-efficient, safe, and effective integrated recovery pathway alongside cure, setting measurable goals for national implementation has been taken a step further with the recruitment of a neurorehabilitation trustee, Dr Jane Williams, to the board and to this initiative, and strategic advice from Sir Bruce Keogh, the outgoing NHSE National Clinical Director. We have pursued our request for a face to face audience with childrens cancer commissioners and those responsible for highly specialised funding pertinent to the need for bespoke pituitary tumour services, which has been scheduled for 14th January 2025. This is a significant opportunity granted to SUCCESS and is an early hopeful indication of the appropriateness of our approach to lobbying through Parliament and NHSE, which also includes an approach to the Department of Health by Dr Spoudeas through her local MP. We continue to reinforce this group and formalise its governance as part of the Charity's overall structure.

SUCCESS LIFE AFTER CURE LIMITED

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

We need to continue to expand engagement across major paediatric neuroncology centres and decision-makers in NHSE and government to define and endorse a cost-efficient, safe, and effective integrated recovery pathway, setting measurable goals for national implementation. This is something we are currently working on with Lord Sandhurst and our Patron, Dominc Grieve, and will continue to develop further in 2025. We will also continue to collaborate closely with the Children and Young People's Cancer Coalition of Charities and the Brain Tumour APPG, and are alert to any new initiatives launched by the new Labour Department of Health and Social Care [DHSC] in the area of children's cancer, which work streams were first announced by Dame Caroline Dinnenage before the general election.

Additionally, we will begin feasibility assessments about the possibility of developing designated paediatric pituitary centres of expertise, with associated HR-QOL outcome national data registries, integrating new CCLGcommissioned and RCPCH-endorsed national guidelines for rare pituitary tumours affecting <50 CYP annually. This will be subject to funding, but continues to be a priority for the charity.

Clinical Advisory Experts/Group.

Launched in early 2024, this initiative, started by our founder and now led by trustee Dr Jane Williams with Dr Jenny Limond as deputy, brought together NHSE commissioning and health research experts in neuroncology, neurosurgery, neuropsychology, neuroendocrinology and allied therapy. The goal is to ensure we support equitable healthcare evaluation studies in the survivorship field and quality improvements in any medically-related projects we undertake or commission. Membership of this Expert Group has generated significant support from the clinical community which can be found on our website.

Parent Council

2025 will also see the development of a Parent Council with a lead parent trustee and at least six volunteer parents of survivors already engaged and charged with developing further engagement from their community to feedback to the Board on a quarterly basis.

Survivor Council

In recognition of the importance of the survivor voice to be heard at the board, we are also launching a Survivor Council to work alongside the parents' council with a lead survivor trustee and deputy, ensuring the survivor voice is formally recognised in the Governance of the Charity, and reporting to the Board on a quarterly basis.

Contribution made by volunteers

In the absence of a large charitable endowment at its start-up, much of the Charity's activity, is necessarily still carried out by volunteers, including the role of our CEO which is undertaken by our Founder trustee. As well as the Board of Trustees, other volunteers have given time and expertise with matters such as organising events, producing educational and information resources and providing support and legal and governance advice. The charity has had a part-time administrator for 3 years and a fixed term appointment part-time project manager this year, utilising consultants to assist with the operations, web-site development, marketing and communications, and fundraising. Due to limited funding, the Charity and the Board are restructuring in 2025, to increase volunteer involvement and skills, prioritise income generation and fundraising, optimise the activities of committees reporting to the board, and limit administrative expenses.

SUCCESS LIFE AFTER CURE LIMITED

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Achievements and performance

Significant activities and achievements against objectives

Performance of fundraising activities against objectives set

Sector challenges

SUCCESS continues to face significant fundraising difficulties as competition for grants and donations intensifies in an increasingly challenging environment for the third-sector. Further, this chronic survivorship area of cancer care is notoriously difficult to secure funding for, competing as it does with the much easier fundraising call for the cancer cure itself. Securing sustainable funding has thus become doubly harder. Many corporate donors only prioritize larger charities, and/or make donations proportionate to 10% of annual income streams, making it difficult for small, specialist organisations like SUCCESS to access critical funding streams. The eventual drying up of EU funding since Brexit, and the economic uncertainty has generated unprecedented competition for grants from Trusts, Foundations and the National Lottery and reduced individual giving, while complex grant application processes require resources that small charities must use prudently. Despite these difficulties, we remain committed to our mission, focusing on diversifying income streams and strengthening donor engagement. We have, as a Board, decided to invest more fully in an integrated CRM system, consolidate our stakeholder base, create a legacy opoortunity and engage in more specific targetting of donor groups to maximise our ability to raise funds from a category of donors more likely to provide initial funds.

Engaging our community

A key strategy for overcoming these sector challenges has been to strengthen our engagement with our community of fundraisers and donors through meaningful events. These not only serve as vital fundraising opportunities but also enable stronger meaningful connections, ensuring our supporters feel involved in our mission and appreciate the lasting impact of their contributions.

They included:

SUCCESS LIFE AFTER CURE LIMITED

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

SUCCESS Will continue to build on what has now become an iconic event in its community and fundraising diary, and has committed to venues in 2025 and 2026.

Overall, SUCCESS managed to generate income amounting to £114,900 across all activities. We are enormously grateful to all our supporters and donors, large and small for this vital development support, which means so much to us, our board and to our beneficiaries at this early time of our foundation.

SUCCESS LIFE AFTER CURE LIMITED

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Financial review

Overview

SUCCESS's income has decreased from £117,355 in 2023 to £114,975 in 2024, boosted by restricted funds of £47,000 including a personal donation of £25,000 from SUCCESS's founder, Helen Spoudeas, towards our Digital Therapy project. Other material donations included Pfizer Global Shared Services Europe amounting to £12,000, BUPA Cromwell's £10,000 sponsorship of our 'Light in the Shadows' Christmas Carol Concert at GPIM Ltd's £5,000 contribution towards the same appeal.

The Summer of FUN-draising generated twice as much income this year as in 2023; this is a cost effective activity the Charity will continue to focus on as a major fundraising event in its calendar, together with the Carol Concert which generated £33,428 in 2024 (some 65% more than in 2023). The Charity was less successful than in previous year in generating sustainable, other income from its supporter base, amounting to just £7,813 (against approximately £16,476 last year). Planned investment in a more integrated CRM will hopefully provide opportunities for more targeted campaigns aimed at generating a regular income from its donor base.

In 2024, SUCCESS committed £96,409 to charitable activities (71% of its total expenditure - against a similar level last year), with £46,376 attributable to the conference and roadshow, £22,500 to fund the Gap Analysis (drawn from restricted reserves brought forward). The conference used to attract more pharmaceutical companies prepared to support this type of event, but obtaining funds from this group of stakeholders has become increasingly restricted and challenging. The 2025 conference and roadshow will go ahead, with some restricted funds of £15,000 secured from William Arthur Rudd trust, but it is anticipated this will be a cost leader in the context of SUCCESS' endeavour to grow its base of supporters and deliver on its mission.

The Carol Concert fundraising event was delivered at a similar cost to last year, but managed to generate more income, providing a greater contribution to general reserves.

Overall, the Charity made a deficit of £26,857 in 2024 against a deficit of £11,300 in 2023 further depleting its general reserves.

Included in prepayment and accrued income of £5,980 is £6,072 deposit for SUCCESS' 2025 Annual Conference, and accruals and deferred income includes a balance of £15,000 from the William Arthur Memorial Trust towards our conference programme in 2025, and a provision for costs of £3,100 attributable to the Norwich Cathedral Choir incurred in December 2024.

As in previous years, the charity's limited capacity to generate sustainable revenue streams for its initiatives and the staffing salaries to support them continues to be a material risk. To address this, SUCCESS engaged a business consulting and fundraising firm two years ago. Excluding costs attributable to the Survivorship Gap Analysis Study funded by reserves brought forward, this cost represents 25% of the total in 2024 (an increase from 21% last year). The expectation is that this proportion will continue to increase in 2025 as the Charity loses the administrator role and shifts its investment in salaried costs (fixed costs) to variable costs, to address economic uncertainties faced by the sector and continue to operate as a going concern.

The Board and Risk Committee continue to acknowledge that an urgent focus on fundraising is needed to deliver on the broader projects identified as part of its strategic plan.

SUCCESS LIFE AFTER CURE LIMITED

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

Reserves policy

The Charity continues to monitor reserves on an ongoing basis, including at the last two Board Meetings on 6th December 2024 and 28th January 2025. The Board appreciates the need to balance reserves with sufficient fund allocation for progression of charitable activities as detailed above.

Total unrestricted reserves carried forward stand at £71,759 for the year ended 31 December 2024 (a decline of approximately 30% on last year), with an additional £31,317 restricted funds allocated to the delayed launch of SUCCESS' Digital Therapy project. Total reserves therefore stand at £103,076 (against £129,993 at the end of last year).

The Trustees continue to believe a formulaic reserve policy is not commercially meaningful, but agrees to monitor costs and revenues on a quarterly basis as part of its risk and control procedures. Current reserves cover at least six months of operational expenses, now that a reorganisation to reduce fixed costs has been effected. At this stage, the Trustees feel this is a reasonable commercial buffer to maintain and review it quarterly at Board meetings.

Principal funding sources

The charity's principal sources of funds (including any fundraising)

The charity raises income through individual giving, community fundraising, corporate support and grants. Last year, we registered with Stripe and Just giving, receiving donations through these methods. Credit card and PayPal donations can be made directly through the website. In 2025, a fundraising strategy will be developed with a new fund-raising committee in a re-aligned board structure, alongside a refreshed board of more trustees with time and relevant skill sets. Our goal is to provide detailed 12 month, and high level 5- year fundraising targets, as well as a legacy programme, against which we can budget for the projects we aim to deliver.

Major risks

Risk Policy

The Risk Committee conducts a review of the major risks to which the charity is exposed using the Charity Commission framework and has a risk register updated at least annually by the Governance Committee and presented to the Board).

Where appropriate, systems or procedures have been established to mitigate the risks the charity faces, including ensuring all trustees and patient facing staff have appropriate DBS checks within 6 weeks of appointment as well as updating our safeguarding and recruitment policies, ensuring safeguarding training at the earliest opportunity as a condition of appointment, given the vulnerable children and adults we help. We also take cybersecurity seriously and are aware our safety needs testing as a priority, despite the limited funds to allocate to this at present. We currently have two levels of authorisation for all financial transactions, though one is salaried staff and requires reconsideration.

The main risks identified remain similar to previous years:

SUCCESS LIFE AFTER CURE LIMITED

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Structure, governance and management Governing document

Success is a charitable company limited by guarantee and established under its Memorandum and Articles of Association. In the event of the company being wound up every member of the charity undertakes to contribute such amount as may be required (not exceeding £1).

Trustee selection methods including details of any constitutional provisions:

The Board spent time reviewing the Charity Commission guidance, the Charity Governance Code and other governance reference material. Trustee role descriptions and a Code of Conduct were produced and implemented.

The trustees, who are also the directors for the purpose of company law, and who served during the year and up to the 31[st] December 2024 were:

Philip Austin Jane Hobson Hugh Stewart Jennifer Limond Marco Previero Dr Helen Spoudeas Dr Jane Williams Richard Crowther (Retired by rotation, 9[th] February 2024)

Recruitment and appointment of trustees

Trustee recruitment, selection and succession planning will be agreed as part of the ongoing governance of the organisation. This will include consideration of the requirements for a diverse board membership, ensuring that trustees have different backgrounds and experiences to enable better decisions.

A comprehensive programme of governance training was included in board meetings, to ensure that trustees were aware of the responsibilities and expectations of them, and to be able to review their effectiveness. Plans to ensure ongoing board development and training are in progress.

The charity is governed by the Board of Trustees, with advice and support from external freelance consultants, who operate as project managers for some aspects of charitable activity. A series of sub-groups [committees] and steering [Advisory] groups support the work of the Board and the operational delivery of its charitable aims and objectives. External HR and legal advice is provided on a pro bono basis by a legal firm.

The charity operates within the wider environment of children's cancer, brain tumour and brain injury charities and services and has formed links with other charities and NHS services, through informal discussions, with the ultimate aim of enhancing the lives of childhood brain tumour survivors.

SUCCESS LIFE AFTER CURE LIMITED

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

The trustees' report was approved by the Board of Trustees.

Hugh Stewart Director 4 April 2025

SUCCESS LIFE AFTER CURE LIMITED

STATEMENT OF TRUSTEES' RESPONSIBILITIES

FOR THE YEAR ENDED 31 DECEMBER 2024

The trustees, who are also the directors of Success for the purpose of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company Law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year.

In preparing these financial statements, the trustees are required to:

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the charity and financial information included on the charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Approved by the Management Committee and signed on its behalf by

Hugh Stewart (Chair)

Director

SUCCESS LIFE AFTER CURE LIMITED

INDEPENDENT EXAMINER'S REPORT

TO THE TRUSTEES OF SUCCESS LIFE AFTER CURE LIMITED

I report to the trustees on my examination of the financial statements of Success Life After Cure Limited (the charity) for the year ended 31 December 2024.

Responsibilities and basis of report

As the trustees of the charity (and also its directors for the purposes of company law), you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006.

Having satisfied myself that the financial statements of the charity are not required to be audited under Part 16 of the Companies Act 2006 and are eligible for independent examination, I report in respect of my examination of the charity's financial statements carried out under section 145 of the Charities Act 2011. In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the Charities Act 2011.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Tom Wilcox

Counterculture Partnership LLP Bank Chambers Main Street Hawes North Yorkshire DL8 3QL 8 April 2025

SUCCESS LIFE AFTER CURE LIMITED

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2024

Notes
Income from:
Donations and legacies
3
Total income
Expenditure on:
Raising funds
4
Charitable activities
5
Total expenditure
Net income/(expenditure)
Transfers between
funds
Net movement in
funds
6
Reconciliation of funds:
Fund balances at 1 January
2024
102,896
27,037
Fund balances at 31
December 2024
71,759
31,317
Unrestricted
funds
Restricted
funds
2024
2024
£
£
67,975
47,000
67,975
47,000
7,670
-
90,979
43,183
98,649
43,183
(30,674)
3,817
(463)
463
(31,137)
4,280		 129,933
125,373
15,860
103,076
102,896
27,037
Total Unrestricted
funds
Restricted
funds
2024
2023
2023
£
£
£
114,975
79,973
37,382
114,975
79,973
37,382
7,670
11,079
4,374
134,162
80,535
32,667
141,832
91,614
37,041
(26,857)
(11,641)
341
-
(10,836)
10,836
(26,857)
(22,477)
11,177		 141,233
129,933
Total
2023
£
117,355
117,355
15,453
113,202
128,655
(11,300)
-
(11,300)

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

SUCCESS LIFE AFTER CURE LIMITED

BALANCE SHEET

AS AT 31 DECEMBER 2024

2024
Notes
£
Fixed assets
Tangible assets
10
Current assets
Debtors
11
16,750
Cash at bank and in hand
115,322
132,072
Creditors: amounts falling due within
one year
12
(29,464)
Net current assets
Total assets less current liabilities
The funds of the charity
Restricted income funds
14
Unrestricted funds
15		 2023
£
£
468
48,785
94,950
143,735
(14,011)
102,608
103,076
31,317
71,759
103,076		 £
209
129,724
129,933
27,037
102,896
129,933

The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 December 2024.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the trustees on 4 April 2025

Hugh Stewart Director

Company registration number 11785842 (England and Wales)

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

1 Accounting policies

Charity information

Success Life After Cure Limited is a private company limited by guarantee incorporated in England and Wales. The registered office is 280 Bishopsgate, London, EC2M 4RB.

1.1 Accounting convention

The financial statements have been prepared in accordance with the charity's Memorandum of Association, the Companies Act 2006, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)". The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities not to prepare a statement of cash flows.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors or grantors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

Endowment funds are subject to specific conditions by donors that the capital must be maintained by the charity.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

1 Accounting policies

(Continued)

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.

1.6 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings 20% on reducing balance basis Computer equipment 33% on reducing balance basis

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

1.7 Impairment of fixed assets

At each reporting end date, the charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.8 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.9 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

1 Accounting policies

(Continued)

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

1.10 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3 Income from donations and legacies

Unrestricted Restricted **Total ** Unrestricted Restricted Total
funds funds funds funds
2024 2024 2024 2023 2023 2023
£ £ £ £ £ £
Donations and gifts 67,975 47,000 114,975 79,973 37,382 117,355

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

4 Expenditure on raising funds

Unrestricted Restricted **Total ** Unrestricted Restricted Total
funds funds funds funds
2024 2024 2024 2023 2023 2023
£ £ £ £ £ £
Fundraising and publicity
Seeking donations, grants
and legacies 7,670 - 7,670 11,079 4,374 15,453

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

5 Costs of charitable activities by fund type

Unrestricted
Restricted
Funds
Funds
2024
2024
£
£
Amplify voice of survivors
4,885
-
Reduce solical isolation
42,653
5,000
Catalyst for post-cure recovery
5,688
38,183
Support costs
37,752
-
90,978
43,183
Costs of charitable activity by
activity type
Undertaken
Support
directly
costs
£
£
Support costs
Amplify voice of survivors
4,885
1,913
Reduce solical isolation
47,653
18,660
Catalyst for post-cure recovery
43,872
17,179
96,409
37,752
Analysis of support costs
Amplify
Reduce
Catalyst
voice
isolation
post-cure
£
£
£
Managment
397
3,877
3,569
General overheads
1,242
12,115
11,153
Website development
122
1,192
1,097
General Governance
151
1,476
1,359
1,913
18,659
17,179		 2024
£
4,885
47,653
43,872
37,752
134,162
2024
£
6,798
66,313
61,051
134,162
2024
£
7,844
24,510
2,411
2,987
37,752		 2023
£
6,559
60,620
13,403
32,620
113,202
2023
£
9,215
85,171
18,816
113,203
2023
£
17,031
8,201
6,217
1,171
32,720

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

6 Net movement in funds 2024 2023
£ £
The net movement in funds is stated after charging/(crediting):
Fees payable for the independent examination of the charity's financial
statements - -
Depreciation of owned tangible fixed assets 180 -

7 Trustees

None of the trustees (or any persons connected with them) received any remuneration or benefits from the charity during the year.

8 Employees

The average monthly number of employees during the year was:

2024 2023
Number Number
1 1

There were no employees whose annual remuneration was more than £60,000.

9 Taxation

The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.

10 Tangible fixed assets
Fixtures and Computer Total
fittings equipment
£ **£ ** £
Cost
At 1 January 2024 209 - 209
Additions - 648 648
Disposals (209) - (209)
At 31 December 2024 - 648 648
Depreciation and impairment
Depreciation charged in the year - 180 180
At 31 December 2024 - 180 180
Carrying amount
At 31 December 2024 - 468 468
At 31 December 2023 209 - 209

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

11 Debtors

Debtors
Amounts falling due within one year:
Trade debtors
Other debtors		 2024
£
10,770
5,980
16,750		 2023
£
1,534
47,251
48,785

12 Creditors: amounts falling due within one year

Notes
Deferred income
13
Trade creditors
Accruals		 2024
£
20,004
8,210
1,250
29,464		 2023
£
-
12,839
1,172
14,011

13 Deferred income

Deferred income
2024 2023
**£ ** £
Other deferred income 20,004 -

Deferred income is included in the financial statements as follows:

Deferred income is included within:
Current liabilities
Movements in the year:
Deferred income at 1 January 2024
Resources deferred in the year
Deferred income at 31 December 2024		 2024
£
20,004
-
20,004
20,004		 2023
£
-
-
-
-

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

14 Restricted funds

The restricted funds of the charity comprise the unexpended balances of donations and grants held on trust subject to specific conditions by donors as to how they may be used.

At 1 January Incoming Resources Transfers At 31
2024 resources expended December
2024
£ £ £ £ £
- - - - -
Conference - 12,000 (12,000) - -
Nurse Appeall/MDT 22,037 - (22,500) 463 -
ReAbility 5,000 30,000 (3,683) - 31,317
Carol Concert 2024 - 5,000 (5,000) - -
27,037 47,000 (43,183) 463 31,317
Previous year: At 1 January Incoming Resources Transfers At 31
2023 resources expended December
2023
£ £ £ £ £
- - - - -
Conference 11,760 11,930 (23,690) - -
Nurse Appeal 4,100 20,000 (2,063) - 22,037
ReAbility - 5,452 (11,288) 10,836 5,000
15,860 37,382 (37,041) 10,836 27,037

Note to the restricted funds

SUCCESS received a £12,000 grant for patient benefit from Pfizer Global Shared Services Europe for the 2024 conference. ReAbility is an online rehabilitative tool that helps people with neurological damage get better; and enables them to lead better lives. The Charity was the beneficiary of a donation of £25,000 from Helen Spoudeas, restricted for the use of this project, and £5,000 received from The Albert Hunt Trust as a contribution towards this project, making up £30,000. £5,000 related to sponsorship of the Carol Concert from GPIM Ltd as contribution towards the choir, venue and production costs.

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

15 Unrestricted funds

The unrestricted funds of the charity comprise the unexpended balances of donations and grants which are not subject to specific conditions by donors and grantors as to how they may be used. These include designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

At 1 January Incoming Resources Transfers At 31
2024 resources expended December
2024
£ £ £ £ £
General funds 102,896 67,975 (98,649) (463) 71,759
Previous year: At 1 January Incoming Resources Transfers At 31
2023 resources expended December
2023
£ £ £ £ £
General funds 125,373 79,973 (91,614) (10,836) 102,896

16 Analysis of net assets between funds

Unrestricted Restricted Total
funds funds
2024 2024 2024
£ £ £
At 31 December 2024:
Tangible assets 468 - 468
Current assetsl/(liabilities) 71,291 31,317 102,608
71,759 31,317 103,076
Unrestricted Restricted Total
funds funds
2023 2023 2023
£ £ £
At 31 December 2023:
Tangible assets 209 - 209
Current assetsl/(liabilities) 102,687 27,037 129,724
102,896 27,037 129,933

17 Related party transactions

There were no disclosable related party transactions during the year (2023 - none).